280 related articles for article (PubMed ID: 24601786)
1. An epigenetic biomarker panel for glioblastoma multiforme personalized medicine through DNA methylation analysis of human embryonic stem cell-like signature.
Chiang JH; Cheng WS; Hood L; Tian Q
OMICS; 2014 May; 18(5):310-23. PubMed ID: 24601786
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide methylomic and transcriptomic analyses identify subtype-specific epigenetic signatures commonly dysregulated in glioma stem cells and glioblastoma.
Pangeni RP; Zhang Z; Alvarez AA; Wan X; Sastry N; Lu S; Shi T; Huang T; Lei CX; James CD; Kessler JA; Brennan CW; Nakano I; Lu X; Hu B; Zhang W; Cheng SY
Epigenetics; 2018; 13(4):432-448. PubMed ID: 29927689
[TBL] [Abstract][Full Text] [Related]
3. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients.
Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A
Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic modulation of the drug resistance genes MGMT, ABCB1 and ABCG2 in glioblastoma multiforme.
Oberstadt MC; Bien-Möller S; Weitmann K; Herzog S; Hentschel K; Rimmbach C; Vogelgesang S; Balz E; Fink M; Michael H; Zeden JP; Bruckmüller H; Werk AN; Cascorbi I; Hoffmann W; Rosskopf D; Schroeder HW; Kroemer HK
BMC Cancer; 2013 Dec; 13():617. PubMed ID: 24380367
[TBL] [Abstract][Full Text] [Related]
5. A novel gene signature based on five glioblastoma stem-like cell relevant genes predicts the survival of primary glioblastoma.
Chai R; Zhang K; Wang K; Li G; Huang R; Zhao Z; Liu Y; Chen J
J Cancer Res Clin Oncol; 2018 Mar; 144(3):439-447. PubMed ID: 29299749
[TBL] [Abstract][Full Text] [Related]
6. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
[TBL] [Abstract][Full Text] [Related]
7. A 4-miRNAs signature predicts survival in glioblastoma multiforme patients.
Yuan GQ; Wei NL; Mu LY; Wang XQ; Zhang YN; Zhou WN; Pan YW
Cancer Biomark; 2017 Dec; 20(4):443-452. PubMed ID: 28869437
[TBL] [Abstract][Full Text] [Related]
8. The significance of MGMT methylation in Glioblastoma Multiforme prognosis.
Rao AM; Quddusi A; Shamim MS
J Pak Med Assoc; 2018 Jul; 68(7):1137-1139. PubMed ID: 30317322
[TBL] [Abstract][Full Text] [Related]
9. Podocalyxin-like protein is expressed in glioblastoma multiforme stem-like cells and is associated with poor outcome.
Binder ZA; Siu IM; Eberhart CG; Ap Rhys C; Bai RY; Staedtke V; Zhang H; Smoll NR; Piantadosi S; Piccirillo SG; Dimeco F; Weingart JD; Vescovi A; Olivi A; Riggins GJ; Gallia GL
PLoS One; 2013; 8(10):e75945. PubMed ID: 24146797
[TBL] [Abstract][Full Text] [Related]
10. Integrative analysis of DNA methylation and gene expression to identify key epigenetic genes in glioblastoma.
Jia D; Lin W; Tang H; Cheng Y; Xu K; He Y; Geng W; Dai Q
Aging (Albany NY); 2019 Aug; 11(15):5579-5592. PubMed ID: 31395792
[TBL] [Abstract][Full Text] [Related]
11. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
[TBL] [Abstract][Full Text] [Related]
12. A novel risk signature with 6 RNA binding proteins for prognosis prediction in patients with glioblastoma.
Huang QR; Li JW; Pan XB
Medicine (Baltimore); 2021 Dec; 100(48):e28065. PubMed ID: 35049227
[TBL] [Abstract][Full Text] [Related]
13. A novel prognostic six-CpG signature in glioblastomas.
Yin AA; Lu N; Etcheverry A; Aubry M; Barnholtz-Sloan J; Zhang LH; Mosser J; Zhang W; Zhang X; Liu YH; He YL
CNS Neurosci Ther; 2018 Mar; 24(3):167-177. PubMed ID: 29350455
[TBL] [Abstract][Full Text] [Related]
14. Glioblastoma Multiforme: Fewer Tumor Copy Number Segments of the
Lehrer S; Rheinstein PH; Rosenzweig KE
Cancer Genomics Proteomics; 2018; 15(4):273-278. PubMed ID: 29976632
[TBL] [Abstract][Full Text] [Related]
15. A long non-coding RNA signature in glioblastoma multiforme predicts survival.
Zhang XQ; Sun S; Lam KF; Kiang KM; Pu JK; Ho AS; Lui WM; Fung CF; Wong TS; Leung GK
Neurobiol Dis; 2013 Oct; 58():123-31. PubMed ID: 23726844
[TBL] [Abstract][Full Text] [Related]
16. Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients.
Yong WH; Shabihkhani M; Telesca D; Yang S; Tso JL; Menjivar JC; Wei B; Lucey GM; Mareninov S; Chen Z; Liau LM; Lai A; Nelson SF; Cloughesy TF; Tso CL
PLoS One; 2015; 10(10):e0141334. PubMed ID: 26506620
[TBL] [Abstract][Full Text] [Related]
17. Apparent diffusion coefficient obtained by magnetic resonance imaging as a prognostic marker in glioblastomas: correlation with MGMT promoter methylation status.
Romano A; Calabria LF; Tavanti F; Minniti G; Rossi-Espagnet MC; Coppola V; Pugliese S; Guida D; Francione G; Colonnese C; Fantozzi LM; Bozzao A
Eur Radiol; 2013 Feb; 23(2):513-20. PubMed ID: 22875158
[TBL] [Abstract][Full Text] [Related]
18. Large-Scale Analysis Reveals Gene Signature for Survival Prediction in Primary Glioblastoma.
Prasad B; Tian Y; Li X
Mol Neurobiol; 2020 Dec; 57(12):5235-5246. PubMed ID: 32875483
[TBL] [Abstract][Full Text] [Related]
19. Methylation of O6-methylguanine DNA methyltransferase and loss of heterozygosity on 19q and/or 17p are overlapping features of secondary glioblastomas with prolonged survival.
Eoli M; Menghi F; Bruzzone MG; De Simone T; Valletta L; Pollo B; Bissola L; Silvani A; Bianchessi D; D'Incerti L; Filippini G; Broggi G; Boiardi A; Finocchiaro G
Clin Cancer Res; 2007 May; 13(9):2606-13. PubMed ID: 17473190
[TBL] [Abstract][Full Text] [Related]
20. Defining a prognostic score based on O6-methylguanine-DNA methyltransferase cut-off methylation level determined by pyrosequencing in patients with glioblastoma multiforme.
De Carlo E; Gerratana L; De Maglio G; Buoro V; Cortiula F; Gurrieri L; Isola M; Fasola G; Puglisi F; Pizzolitto S; Rizzato S
J Neurooncol; 2018 Dec; 140(3):559-568. PubMed ID: 30132165
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
